Palvella Therapeutics
PVLA
142.85
-2.92
-2.00%
Palvella Therapeutics
US · PVLA
#2822 by market cap
Listed 1970
142.85
-2.92
-2.00%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
William Blair Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $266Market Newswire · 2026/10/16
-
Rating change
Cantor Fitzgerald Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $210Market Newswire · 2026/10/22
-
Rating change
H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Cuts Target Price to $246Market Newswire · 2026/10/12
-
Clear Street Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $220Market Newswire · 2026/10/21
-
Rating change
LifeSci Capital Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $225Market Newswire · 2026/7/22
-
A Quick Look at Today's Ratings for Palvella Therapeutics(PVLA.US), With a Forecast Between $207 to $246Market Newswire · 2026/11/7
-
Rating change
H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $246Market Newswire · 2026/10/20
-
Rating change
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Palvella Therapeutics (PVLA) and Mineralys Therapeutics, Inc. (MLYS)TipRanks · 2026/10/12
-
CCORF Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Raises Target Price to $243Market Newswire · 2026/11/9
-
Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Cuts Target Price to $232Market Newswire · 2026/10/29
-
Palvella Therapeutics (PVLA.US) will release its financial report before the market opens on November 5.Market Newswire · 2026/10/31
-
Rating change
H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $270Market Newswire · 2026/8/6
-
Rating change
Chardan Capital Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $240Market Newswire · 2026/9/21
-
Rating change
Truist Financial Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $207Market Newswire · 2026/8/5
-
Rating change
A Quick Look at Today's Ratings for Palvella Therapeutics(PVLA.US), With a Forecast Between $207 to $267Market Newswire · 2026/8/5
-
Rating change
Oppenheimer Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $210Market Newswire · 2026/8/5
-
Rating change
Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240Market Newswire · 2026/9/10
-
Rating change
BTIG Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $215Market Newswire · 2026/10/13
-
Rating change
Raymond James Maintains Palvella Therapeutics(PVLA.US) With Buy RatingMarket Newswire · 2026/10/16
-
Rating change
TD Cowen Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Raises Target Price to $267Market Newswire · 2026/7/22
-
Rating change
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA)TipRanks · 2026/7/1
-
Rating change
CCORF Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $227Market Newswire · 2026/6/25
-
Rating change
Stifel Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $250Market Newswire · 2026/6/24
-
Form 144 | Palvella Therapeutics(PVLA.US) Director Proposes to Sell 3.7 Million in Common StocksMarket Newswire · 2026/10/14
-
Rating change
A Quick Look at Today's Ratings for Palvella Therapeutics(PVLA.US), With a Forecast Between $210 to $270Market Newswire · 2026/5/22
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Palvella Therapeutics discussion 0 comments